NurOwn® will be made available for ALS patients who completed all Phase 3 clinical trial assessments and meet specific eligibility criteria NEW YORK, Dec. 14, 2020 /PRNewswire/ -- BrainStorm Cell ...
NEW YORK, June 16, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced new survival data ...
A conference call and webcast will be held Tomorrow, April 9, at 8:00 a.m. Eastern Time NEW YORK, April 8, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of ...
For as long as I've been using a Mac, there have been a couple of software categories that fascinate me. One is outline processing. Over the years I've been in love with programs like Think Tank, MORE ...
NEW YORK, Oct. 28, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the presentation of ...
NEW YORK, July 8, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, is hosting a Key Opinion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results